Company / Financials
Valion Bio, Inc. Financials
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.2M
FY2024 · -36.1% YoY
Net Income
-$8.2M
FY2024 · +18.3% YoY
Profit Margin
-701.0%
FY2024 · net income / revenue
ROE
-230.3%
FY2024 · return on equity
Total Assets
$2.8M
FY2024
Total Debt
-
FY2024
Equity
$3.6M
FY2024
ROA
-293.7%
FY2024 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.2M-36.1% YoYNet Income HistoryProfit after all expenses and taxes-$8.2M+18.3% YoYGross Profit HistoryRevenue minus cost of goods sold$287.0K-4.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$889.0K-42.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$8.2M+18.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$4.8M-19.1% YoYR&D Expense HistoryResearch and development spending$1.7M-4.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$1.0K-50.0% YoYEPS (Basic) HistoryBasic earnings per share-$176.80-69.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$176.80-69.5% YoY